Erschienen in:
01.05.2007 | Editorial
Targeting caspase-1 in sepsis: a novel approach to an old problem
verfasst von:
Gustavo Matute-Bello
Erschienen in:
Intensive Care Medicine
|
Ausgabe 5/2007
Einloggen, um Zugang zu erhalten
Excerpt
More than 500,000 people develop sepsis each year in the USA alone, and approximately 175,000 of them die [
1,
2]. Moreover, the incidence of sepsis has been increasing at an annualized rate of 8.7% [
1]. Sepsis is one of the most common risk factors for acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS), accounting for 89% of all ALI/ARDS cases [
3]. Approximately 30–50% of patients with ALI/ARDS who die have sepsis [
4]. Understandably, the identification of small molecules that can be used as therapeutic agents in the treatment of sepsis has been a major research priority for the past several years. …